Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
Authors' conclusion
We observed low rates of SGLT2 inhibitor and GLP1-RA prescriptions in patients with T2DM irrespective of CKD status. Strategies are needed to improve prescription rates, with a particular focus on patients with high kidney and cardiovascular risk.
Study context
- Population
- Adults with T2D attending Australian primary care practices participating in MedicineInsight36,840 (32.1%) with chronic kidney disease (CKD)
- Participants
- 114,499 adults
- Exposure
- T2D patients with CKD vs without CKD
- With CKDn = 36,840
- Outcome
- Percentage of patients with ≥1 prescription for an SGLT2 inhibitor or a GLP1-RA (assessed separately), CKD vs no CKD
- Follow-up
- 2020-2021
Main finding
As reported in the abstract
≥1 SGLT2 inhibitor prescription
Observational data: associations, not effects.
Further findings
| Outcome | With CKD | Trial target population |
|---|---|---|
| ≥1 GLP1-RA prescription · 2020-2021Assessed separately; part of the outcome of interest | 10.1% | 11.3% |
- ≥1 GLP1-RA prescription: No CKD 8.8%
Factors associated with prescription
- More advanced CKD stage and severely increased albuminuria were associated with a lower likelihood of SGLT2 inhibitor or GLP1-RA being prescribed
Original publication
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset. Diabetes Obes Metab. Published 16 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →